Spring Arrives, but Influenza B Is Rising
As we welcome the arrival of spring and the comfort of warmer days, many may expect the flu season to gradually subside. However, the reality tells a different story. While Influenza A infections are showing a declining trend, Influenza B is now on the rise, continuing to pose a significant public health concern.
Unlike typical seasonal expectations, Influenza B can remain active well into spring, often leading to overlooked infections and delayed diagnosis. This shift underscores the importance of maintaining robust and reliable diagnostic capabilities, especially for accurate differentiation and early detection.
High-Performance Detection You Can Trust
At Cnpair, we are committed to supporting precise and efficient infectious disease diagnostics. Our Influenza B detection solutions are developed with high-performance antibody pairs and optimized antigens, ensuring excellent assay performance on lateral flow (LF).
Even in samples with low viral loads, our products demonstrate strong detection capability, helping to minimize false negatives and improve diagnostic confidence. With outstanding sensitivity and specificity, Cnpair’s solutions have received highly positive feedback from customers worldwide and have been widely adopted in assay development.
Empowering Your Research and Development
Beyond performance, we also focus on consistency and scalability. Our products are manufactured under strict quality control systems to ensure batch-to-batch stability, supporting both research and large-scale diagnostic production needs.
As the epidemiological landscape continues to evolve, reliable raw materials play a critical role in enabling timely and accurate diagnostics. Cnpair remains dedicated to empowering partners with innovative solutions that enhance assay performance and streamline development workflows. To empower your research, we offer free samples for evaluation, helping you accelerate development and validate performance with confidence.